

Section 1: Issuer information	
Name of issuer	EROAD Limited
NZX ticker code	ERD
Class of financial product	Further issue of unquoted Performance Share Rights (PSRs), convertible to EROAD ordinary shares pursuant to the 2024 Grant (2024 Grant) under EROAD's Long Term Incentive Plan (Plan).
ISIN (If unknown, check on NZX website)	NZERDE0001S5
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	39,387
Nominal value (if any)	N/A
Issue/acquisition/redemption price per security	N/A
Nature of the payment (for example, cash or other consideration)	No consideration is payable for the PSRs. The PSRs have a set exercise price of \$0.
Amount paid up (if not in full)	N/A
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	The PSRs for the 2024 Grant comprise 0.021% of the financial products of that class.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	<p>The PSRs issued under the 2024 Grant comprise three tranches.</p> <p>First Tranche</p> <p>The first tranche of PSRs becomes exercisable on a participant remaining employed on 31 March 2026 and in certain other circumstances.</p> <p>Second Tranche</p> <p>The second tranche of PSRs becomes exercisable where EROAD's total shareholder return (TSR) calculated over a period ending after the release of its results for the year ended 31 March 2026 is at least greater than the 40th percentile of the constituents of the</p>

¹ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

	<p>S&P/ASX All Technology Index (XTX). The percentage of PSRs that become eligible for exercise will increase on a straight-line basis from 50% where EROAD's TSR is equal to the 40th percentile of the constituents of the XTX to 100% where EROAD's TSR is equal to or greater than the 60th percentile of the constituents of the XTX. If EROAD's TSR is equal to or greater than the 80th percentile, the percentage eligible for vesting will increase on a straight-line basis up to 200% vesting at the 100th percentile.</p> <p>Third Tranche</p> <p>The third tranche of PSRs becomes exercisable based on the absolute financial performance of EROAD, which is dependent on EROAD's revenue, EBIT and free cash flow assessed on EROAD's financial statements for each relevant year (being the years ending 31 March 2024, 31 March 2025 and 31 March 2026) compared to EROAD's 3 - year budget set at the beginning of the 2024 Grant, as well as EROAD's cumulative performance over that time. Between 85% and 130% of the PSRs may become exercisable depending on achievement. If performance is less than 85%, then no PSRs will vest. Share rights vest subject to the terms and conditions outlined in EROAD's Long Term Incentive Plan Rules.</p> <p>On vesting, PSRs entitle the holder to one ordinary share in EROAD for no cash payment, subject to adjustment in accordance with the plan rules, ranking equally with all other EROAD Limited ordinary shares.</p> <p>The PSRs have a set exercise price of \$0.</p>
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	<p>Issue of 39,387 PSRs for the FY24 Grant under EROAD's Long Term Incentive Plan. Further background regarding EROAD's FY24 Remuneration</p>

Updated as at June 2023

	<p>Framework and the Plan can be found in EROAD's FY24 and FY25 Remuneration Reports released to the NZX and ASX on 23 May 2024 and 26 May 2025.</p> <p>Board resolution dated 30 June 2023.</p>
<p>Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.</p>	<p>EROAD has a total of 5,468,212 PSR's on issue.</p> <p>This total includes this PSR issue, and PSRs issued in connection with the following grants:</p> <ul style="list-style-type: none"> • EROAD FY24 LTI Grant 1,277,782 PSRs • EROAD FY25 LTI Grant 2,316,127 PSRs • EROAD FY26 LTI Grant 1,834,916 PSRs <p>No PSRs or EROAD Limited ordinary shares are held as treasury stock.</p>
<p>In the case of an acquisition of shares, whether those shares are to be held as treasury stock</p>	<p>N/A</p>
<p>Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made</p>	<p>Directors' resolutions dated 30 June 2023.</p> <p>NZX Listing Rule 4.6.1</p>
<p>Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)</p>	<p>See above.</p> <p>Share Rights are not transferrable and do not entitle the holder to receive dividends or other distributions or vote in respect of EROAD ordinary shares although under the terms of the plan an additional number of shares will be issued on conversion of fully vested PSRs to reflect</p>

	dividends paid on EROAD Limited shares prior to exercise. Any ordinary shares issued on the valid exercise of PSRs will rank equally with existing ordinary shares.
Date of issue/acquisition/redemption ²	17/12/2025
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Eleanor Koningham
Contact person for this announcement	Eleanor Koningham
Contact phone number	+64 2102761650
Contact email address	Eleanor.koningham@eroad.com
Date of release through MAP	17/12/2025

² Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).

Section 1: Issuer information	
Name of issuer	EROAD Limited (EROAD)
NZX ticker code	ERD
Class of financial product	Further issue of unquoted Performance Share Rights (<i>PSRs</i>), convertible to EROAD ordinary shares pursuant to the 2025 Grant (<i>2025 Grant</i>) under EROAD's Long Term Incentive Plan (<i>Plan</i>).
ISIN (If unknown, check on NZX website)	NZERDE0001S5
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	14,693
Nominal value (if any)	N/A
Issue/acquisition/redemption price per security	N/A
Nature of the payment (for example, cash or other consideration)	No consideration is payable for the PSRs. The PSRs have a set exercise price of \$0.
Amount paid up (if not in full)	N/A
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence)	The PSRs for the 2025 Grant comprise 0.008% of the financial products of that class.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	<p>The PSRs issued under the 2025 Grant comprise three tranches.</p> <p>First Tranche</p> <p>The first tranche of PSRs becomes exercisable on a participant remaining employed on 31 March 2027 and in certain other circumstances.</p> <p>Second Tranche</p> <p>The second tranche of PSRs becomes exercisable where EROAD's total shareholder return (<i>TSR</i>) calculated over a period ending after the release of its results for the year ended 31 March 2027 is at least greater than the 40th percentile of the constituents of the S&P/ASX All Technology Index</p>

(XTX). The percentage of PSRs that become eligible for exercise will increase on a straight-line basis from 50% where EROAD's TSR is equal to the 40th percentile of the constituents of the XTX to 100% where EROAD's TSR is equal to or greater than the 60th percentile of the constituents of the XTX. If EROAD's TSR is equal to or greater than the 80th percentile, the percentage eligible for vesting will increase on a straight-line basis up to 200% vesting at the 100th percentile.

Third Tranche

The third tranche of PSRs becomes exercisable based on the absolute financial performance of EROAD, which is dependent on EROAD's revenue, EBIT and free cash flow assessed on EROAD's financial statements for each relevant year (being the years ending 31 March 2025, 31 March 2026 and 31 March 2027) compared to EROAD's 3-year budget set at the beginning of the 2025 Grant, as well as EROAD's cumulative performance over that time. Between 85% and 130% of the PSRs may become exercisable depending on achievement. If performance is less than 85%, then no PSRs will vest.

Share rights vest subject to the terms and conditions outlined in EROAD's Long Term Incentive Plan Rules.

On vesting, PSRs entitle the holder to one ordinary share in EROAD for no cash payment, subject to adjustment in accordance with the plan rules, ranking equally with all other EROAD Limited ordinary shares.

The PSRs have a set exercise price of \$0.

Updated as at 17 October 2019

Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	<p>Issue of 14,693 PSRs for the FY25 Grant under EROAD's Long Term Incentive Plan. Further background regarding EROAD's FY25 Remuneration Framework and the Plan can be found in EROAD's FY25 Remuneration Report released to the NZX and ASX on 26 May 2025.</p> <p>Board resolutions dated 25 June 2024 and 25 September 2024.</p>
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	<p>EROAD has a total of 5,482,905 PSRs on issue.</p> <p>This total includes this PSR issue, and PSRs issued in connection with the following grants:</p> <ul style="list-style-type: none"> • EROAD FY24 LTI Grant 1,317,169 PSRs • EROAD FY25 LTI Grant 2,316,127 PSRs • EROAD FY26 LTI Grant 1,834,916 PSRs <p>No PSRs or EROAD Limited ordinary shares are held as treasury stock.</p>
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Board resolutions dated 25 June 2024 and 25 September 2024. NZX Listing Rule 4.6.1.



NEW ZEALAND'S EXCHANGE
TE PAEHOKO O AOTEAROA

Template Capital Change Notice

Updated as at 17 October 2019

Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)

See above.

Share Rights are not transferrable and do not entitle the holder to receive dividends or other distributions or vote in respect of EROAD ordinary shares although under the terms of the plan an additional number of shares will be issued on conversion of fully vested PSRs to reflect dividends paid on EROAD Limited shares prior to exercise.

Any ordinary shares issued on the valid exercise of PSRs will rank equally with existing ordinary shares.

Date of issue/acquisition/redemption	17/12/2025
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Eleanor Koningham
Contact person for this announcement	Eleanor Koningham
Contact phone number	021 0276 1650
Contact email address	Eleanor.koningham@eroad.com
Date of release through MAP	17/12/2025

Section 1: Issuer information	
Name of issuer	EROAD Limited (EROAD)
NZX ticker code	ERD
Class of financial product	Further issue of unquoted Performance Share Rights (<i>PSRs</i>), convertible to EROAD ordinary shares pursuant to the 2026 Grant (<i>2026 Grant</i>) under EROAD's Long Term Incentive Plan (<i>Plan</i>).
ISIN (If unknown, check on NZX website)	NZERDE0001S5
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	70,633
Nominal value (if any)	N/A
Issue/acquisition/redemption price per security	N/A
Nature of the payment (for example, cash or other consideration)	No consideration is payable for the PSRs. The PSRs have a set exercise price of \$0.
Amount paid up (if not in full)	N/A
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence)	The PSRs for the 2026 Grant comprise 0.038% of the financial products of that class.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	<p>The PSRs issued under the 2026 Grant comprise three tranches.</p> <p>First Tranche</p> <p>The first tranche of PSRs becomes exercisable on a participant remaining employed on 31 March 2028 and in certain other circumstances.</p> <p>Second Tranche</p> <p>The second tranche of PSRs becomes exercisable where EROAD's total shareholder return (<i>TSR</i>) calculated over a period ending after the release of its results for the year ended 31 March 2028 is at least greater than the 40th percentile of the constituents of the S&P/ASX All Technology Index</p>

(XTX). The percentage of PSRs that become eligible for exercise will increase on a straight-line basis from 50% where EROAD's TSR is equal to the 40th percentile of the constituents of the XTX to 100% where EROAD's TSR is equal to or greater than the 60th percentile of the constituents of the XTX. If EROAD's TSR is equal to or greater than the 80th percentile, the percentage eligible for vesting will increase on a straight-line basis up to 200% vesting at the 100th percentile.

Third Tranche

The third tranche of PSRs becomes exercisable if at the end of the three-years, the Rule of 40 metric has been achieved. Revenue growth will be calculated by comparing the total revenue for the period ending 31 March 2028 against the revenue for the prior period ending 31 March 2027 (expressed as a %).

Free Cash Flow Margin will be calculated as free cash flow divided by total revenue for the same 12-month period (expressed as a %).

The Rule of 40 score is the sum of these two percentages. Between 85% and 130% of the PSRs may become exercisable depending on achievement. If performance is less than 85%, then no PSRs will vest.

Share rights vest subject to the terms and conditions outlined in EROAD's Long Term Incentive Plan Rules.

On vesting, PSRs entitle the holder to one ordinary share in EROAD for no cash payment, subject to adjustment in accordance with the plan rules, ranking equally with all other EROAD Limited ordinary shares.

The PSRs have a set exercise price of \$0.

Updated as at 17 October 2019

Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	<p>Issue of 70,633 PSRs for the FY26 Grant under EROAD's Long Term Incentive Plan. Further background regarding EROAD's FY26 Remuneration Framework and the Plan will be available in EROAD's FY26 Remuneration Report.</p> <p>Board resolution dated 18 July 2025 and 4 December 2025.</p>
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	<p>EROAD has a total of 5,553,538 PSRs on issue.</p> <p>This total includes this PSR issue, and PSRs issued in connection with the following grants (corrected from prior announcements due to rounding discrepancies):</p> <ul style="list-style-type: none"> • EROAD FY24 LTI Grant 1,317,169 PSRs • EROAD FY25 LTI Grant 2,230,820 PSRs • EROAD FY26 LTI Grant 1,834,916 PSRs <p>No PSRs or EROAD Limited ordinary shares are held as treasury stock.</p>
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	<p>Board resolutions dated 18 July 2025 and 4 December 2025.</p> <p>NZX Listing Rule 4.6.1.</p>



NEW ZEALAND'S EXCHANGE
TE PAEHOKO O AOTEAROA

Template

Capital Change Notice

Updated as at 17 October 2019

Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)

See above.

Share Rights are not transferrable and do not entitle the holder to receive dividends or other distributions or vote in respect of EROAD ordinary shares although under the terms of the plan an additional number of shares will be issued on conversion of fully vested PSRs to reflect dividends paid on EROAD Limited shares prior to exercise.

Any ordinary shares issued on the valid exercise of PSRs will rank equally with existing ordinary shares.

Date of issue/acquisition/redemption	17/12/2025
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Eleanor Koningham
Contact person for this announcement	Eleanor Koningham
Contact phone number	021 0276 1650
Contact email address	Eleanor.koningham@eroad.com
Date of release through MAP	17/12/2025